Recent presentations and scientific papers. Presentations are in Adobe Acrobat format unless otherwise noted.
Scientific Presentations
High Rate of Sustained Virologic Response in Patients with HCV Genotype-1A Infection: A Phase 2 Trial of Faldaprevir, Deleobuvir and PPI-668, with and without Ribavirin (EASL, April 2014)
Rapid and Consistent Virologic Responses in a Phase 2 Trial of a New All-Oral Combination of Faldaprevir, Deleobuvir and PPI-668, with and without Ribavirin, in Patients with HCV Genotype-1a Infection (AASLD, November 2013)
PPI-668, A Potent New Pan-Genotypic HCV NS5A Inhibitor: Phase 1 Efficacy and Safety (AASLD, November 2012)
